# A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors

> **NCT01725555** · PHASE1 · COMPLETED · sponsor: **Axelar AB** · enrollment: 13 (actual)

## Conditions studied

- Solid Tumors
- Hematological Malignancies

## Interventions

- **DRUG:** Fasted treatment: AXL1717
- **DRUG:** Fed treatment: AXL1717

## Key facts

- **NCT ID:** NCT01725555
- **Lead sponsor:** Axelar AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725555, "A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01725555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*